TGTX/TGR-1202/PT$22(from $19)/Too Conservative?
What's particularly encouraging about this PT upgrade(re: TGR-1202, TGTXs PI3Kdelta inhibitor), is that it's predicated on projected CLL revs only,
while we know there's a whole range of other potential B-cell applications(eg. MCL), not to mention a much wider range of potential applications for this high dose, very low tox PI3K in other cancer sectors, as well(where the toxicity of previous PI3Ks limited the use of this class)...
Once it's approved for any use, these other potential applications should receive rapid attention,
and the obvious result should be a proportional(and likely rapid) increase in TGTXs overall market cap.
Therefore, when you bear in mind the above, plus all the other synergies(plus buyout potential)of TGTXs programs, this PT(despite the raise) appears to me to be a little conservative.
Regards,
bw
